The clinical efficacy and safety of a drug is determined by its activity profile across many proteins in the proteome. However, designing drugs with a specific multi-target profile is both complex and difficult. Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery. Here we describe a new approach for the automated design of ligands against profiles of multiple drug targets. The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrable ligands with either specific polypharmacology or exquisite selectivity profiles for G-protein-coupled receptors. Overall, 800 ligandtarget predictions of prospectively designed ligands were tested experimentally, of which 75% were confirmed to be correct. We also demonstrate target engagement in vivo. The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacology.
The clinical efficacy and safety of a drug is determined by its activity profile across many proteins in the proteome. However, designing drugs with a specific multi-target profile is both complex and difficult. Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery. Here we describe a new approach for the automated design of ligands against profiles of multiple drug targets. The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrable ligands with either specific polypharmacology or exquisite selectivity profiles for G-protein-coupled receptors. Overall, 800 ligandtarget predictions of prospectively designed ligands were tested experimentally, of which 75% were confirmed to be correct. We also demonstrate target engagement in vivo. The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacology.
The safety and efficacy of a drug is determined not only by its action on an individual protein, but also by its interactions with many proteins in the proteome. The promiscuous interaction of a drug with undesired proteins frequently causes toxicity 1 and adverse effects 2, 3 . Conversely, a single drug target can be therapeutically insufficient, particularly in complex neuropsychiatric conditions, infectious diseases or cancer [4] [5] [6] . Instead, it is frequently necessary for a drug to engage two or more targets simultaneously for therapeutic efficacy 7 . Psychiatric drugs in particular require multiple activities against several targets to modulate therapeutically complex neuropsychiatric domains including perception, cognition and emotion 4 . However, designing drugs with a specific multi-target profile-to achieve either exquisite selectivity over other drug targets or a desired polypharmacology-is a complex and exceedingly difficult task for medicinal chemistry 8 . Accordingly, methods are needed to enable drugs to be designed a priori against several molecular targets simultaneously. Here we describe a solution to the complex problem of designing ligands against multiple drug target profiles by automated design.
From prediction to design
The problem of designing ligands against a multi-target profile involves the parallel optimization of multiple structure-activity relationships within a desired range of physicochemical properties. The prospect of multi-target drug design has been recently aided by the development of computational methods that show success in predicting the molecular targets of drugs 3, [9] [10] [11] [12] [13] ( Supplementary Fig. 1 ), although such approaches are not intrinsically design methods.
Drug design can be modelled as an evolutionary process of iterative cycles of exploration and analysis 14, 15 . Adaptive design processes are efficient at solving complex, multi-objective problems. Accordingly, we developed an automated, adaptive design approach to optimize ligands against polypharmacological profiles.
Several de novo drug design methods have been proposed previously [16] [17] [18] [19] [20] [21] . However, of those that have been experimentally tested [22] [23] [24] [25] [26] , high affinity ligands have been described only rarely and these are all against a single molecular target objective 24, 26 . In contrast to previous de novo approaches, we mimicked the creative process by automated learning of medicinal chemistry design tactics, applying these automated learning approaches to the generation of analogues, and then prioritizing them relative to a set of objectives (Fig. 1a ). The development of this approach is described below, starting from 'off-target' predictions, progressing to ligand design, and finally to the discovery of novel compounds with predefined multi-target profiles.
Evolution of a drug
James Black proposed that, ''the most fruitful basis for the discovery of a new drug is to start with an old drug'' 27 . Accordingly, we tested whether the algorithm could automate the evolution of new biological activities, starting from a known drug. Donepezil (compound 1) is an acetylcholinesterase inhibitor approved for cognitive enhancement in Alzheimer's disease. Bayesian probabilistic activity models 9 , for 784 molecular targets built from the ChEMBL database 28 , predicted a moderate likelihood that donepezil possessed D4 dopamine receptor activity and a low chance of D2 dopamine receptor activity ( Supplementary Table 1 ). We found donepezil was a moderately potent D4 inverse agonist (inhibition constant K i 5 614 nM) with minimal D2 activity (Supplementary Figs 2 and  3 and Supplementary Tables 2 and 3 ). The D4 inverse agonist activity of donepezil is intriguing given analyses demonstrating a significant improvement in memory in the trail making test with this drug 29 and findings that D4 antagonists can prevent stress-induced cognitive dysfunction in primates 30 .
We tested our method by evolving the structure of donepezil with the dual objectives of improving D2 activity and achieving blood-brain barrier penetration. In our approach the desired multi-objective profile is defined a priori and then expressed as a point in multi-dimensional space termed 'the ideal achievement point'. In this first example the objectives were simply defined as two target properties and therefore the space has two dimensions. Each dimension is defined by a Bayesian score for the predicted activity and a combined score that describes the absorption, distribution, metabolism and excretion (ADME) properties suitable for blood-brain barrier penetration (D2 score 5 100, ADME score 5 50). We then generated alternative chemical structures by a set of structural transformations using donepezil as the starting structure. The population was subsequently enumerated by applying a set of transformations to the parent compound(s) of each generation. In contrast to rules-based or synthetic-reaction-based approaches for generating chemical structures 16, [31] [32] [33] [34] , we used a knowledge-based approach by mining the medicinal chemistry literature 28, 35 . By deriving structural transformations from medicinal chemistry, we attempted to mimic the creative design process 36 ( Supplementary Fig. 4 ). Activity predictions were calculated for each of the enumerated compounds from all Bayesian models. Scores representing the likelihood of central nervous system (CNS) penetration and good ADME properties were calculated using the program StarDrop and combined into a single value. The predicted properties of the enumerated structures were then expressed as points in multi-dimensional space. The generated structures were subsequently ranked by the distance (in multi-dimensional space) between the predicted properties for each structure and the ideal achievement point 37 (Fig. 1b ). Compounds were filtered for novelty, Lipinski's rule of five compliance 38 and synthetic accessibility 39 . The top 10,000 prioritized structures were selected for the next iterative cycle along with 500 random structures from the remaining population. The process was iterated until either a structure close to the objectives was discovered or no further improvements were achieved.
Initially, we evolved a series of isoindoles and prioritized them using our achievement objectives as criteria ( Fig. 1c , Supplementary  Table 4 and Supplementary Fig. 5 ). Eight analogues were then synthesized and tested ( Fig. 2 Table 3 ).
The second highest ranking compound (compound 3)-chosen from the final population of evolved structures -exhibited the highest D2 receptor affinity (K i 5 156 nM). Thus, we successfully evolved the negligible D2 receptor binding activity of donepezil into a series of ligands with higher D2 affinities ( Fig. 2 ). Functionally, compound 3 was a dual D2 inverse agonist and D4 agonist ( Supplementary Fig. 3 ). CNS penetration studies showed that compound 3 penetrates the brain as predicted, with an in vivo brain-blood ratio (BBR) of 0.5.
Although the evolved compounds were selected for the D2 receptor objective, other predicted activities were not selected against. Accordingly, each of the generated compounds had a predicted polypharmacology profile. In general, this set of isoindole analogues was predicted to exhibit promiscuous profiles, with variable activities predicted for multiple serotonergic, adrenergic and dopaminergic receptor subtypes (Supplementary Tables 1 and 5). These predicted promiscuous profiles were subsequently confirmed ( Fig. 2 and Supplementary Tables 2 and 3) , and the predicted multi-target profiles displayed excellent agreement with experimentally determined profiles, thereby implying that the approach can be applied to the de novo design of multi-target agents.
Reducing anti-target activity
The isoindoles exhibited moderately potent affinities for the a 1adrenoceptors (K i values 5 0.9-3,577 nM, mean K i 5 277 nM, Supplementary Table 3 and Supplementary Fig. 2 ). Because a 1adrenoceptor antagonists can induce low blood pressure as a side effect they are considered 'anti-targets' to be avoided in drug design 40 . A common drug design optimization problem is to reduce such antitarget activity while maintaining desired on-target activities. We accordingly evolved the eight newly synthesized isoindoles towards a polypharmacological profile (5-HT 1A serotonin receptor and D2-, D3-and D4-dopamine receptors) with selectivity over the three a 1adrenoreceptors anti-targets (a 1A , a 1B and a 1D ) while maintaining CNS penetration.
To compare evolutionary strategies, the isoindoles were optimized towards polypharmacology objectives with and without highly predicted a 1 activities filtered-out at each generation ( Fig. 3a and Supplementary Fig. 7 and Supplementary Tables 6 and 7 ). In both optimizations benzolactams were ranked the highest (compounds 11a and 10a respectively) ( Fig. 3b and Supplementary Tables 6 and 7) . Six benzolactam analogues were then synthesized on the basis of both sets of objectives (Supplementary Table 8 and Supplementary  Fig. 5 ). Analogues of the benzo-d-lactam (3,4,-dihydroisoquinolin-1(2H)-one) (compounds 9a, 10a and 11a) and benzo-e-lactam (2,3,4,5-tetrahydro-1-H-benzo[c]azepin-1-one) (compounds 9b, 10b and 11b) were synthesized for comparison because both ring systems were highly prioritized. Both the predicted and observed receptor activity profiles for the synthesized benzolactams are shown in Fig. 3b (see also  Supplementary Tables 1 and 3 and Supplementary Fig. 2 ). The 2pyridine-piperazine analogues (compounds 11a and 11b) have the lowest a 1 predictions and, indeed, exhibited the lowest a 1 affinities (mean K i 5 1,131 nM). In agreement with the models, compounds 11a and 11b also have the lowest affinity for all D2-like dopamine receptors of the benzolactams tested. The dichloro-phenylpiperazine analogues (compounds 9a and 9b) exhibited slightly higher a 1 and D2 binding predictions, which were also confirmed experimentally. By contrast, the 2-methoxy phenylpiperazine analogues (compounds 10a and 10b) exhibited potent affinities against the polypharmacology profile of 5-HT 1A , D2, D3 and D4 receptors, but also had the highest a 1 predictions and were confirmed as the most potent against the a 1 receptors (mean K i 5 45.3 nM) ( Fig. 3b ). Receptor profiling of the benzolactam series revealed that compared to the isoindoles, from which the compounds were evolved, the benzolactams achieved the objective of an increased polypharmacology profile for 5-HT 1A , D2, D3 and D4 receptors compared with the a 1 -adrenoceptors (Fig. 3b ). The benzolactams are 11-fold more selective with respect to D2 receptors and 25-fold more selective with respect to the polypharmacology profile than the isoindoles. Notably, the benzolactam compound 9a penetrated the brain, (BBR 5 5.9), as predicted.
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As the benzolactam series was not present in the ChEMBL database (release 1) used to build the Bayesian models, they constituted a novel chemical series for the system to discover 41 . Notably, benzolactam derivatives have recently been independently synthesized and tested as potent D2 and D3 ligands 42 ; however, the broader receptor profiles of the compounds were not evaluated. This observation provides additional verification that the algorithm is capable of generating and prioritizing novel chemical structures equivalent to those devised by medicinal chemists.
Potency optimization
We next explored selectivity in the context of our multi-target objectives and asked whether we could optimize potent, selective, CNSpenetrant D4 receptor ligands starting from the chemical structure of donepezil. We executed the optimization in two stages; first we optimized for D4 potency and brain penetrability (Fig. 4a ), and then for D4 selectivity (Fig. 4b) . A series of 2-methylindoline derivatives with predicted high D4 activity was evolved from donepezil after six generations ( Fig. 4a and Supplementary Fig. 9 ). Notably, compounds belonging to a 2,3-dihydro-indol-1-yl chemotype were dominant in the prioritized set (Supplementary Table 9 ). Compounds 12 and 13, which both belong to the 2,3-dihydro-indol-1-yl class, were then selected for testing ( Supplementary Figs 5 and 8 ). The highest ranking compound, 12, was inactive, whereas compound 13, the third-highestranking design out of the final population, was the most potent D4 ligand among all tested compounds (D4 K i 5 8.9 nM). Through the process of optimization, compound 13 represents a 69-fold increase in affinity over donepezil. In contrast to the isoindole and benzolactams analogues, compound 13 is predicted to be a highly selective D4 ligand with 95-fold selectivity over 5-HT 2B and weak affinities greater than 1 mM for only five other receptors in our panel of G-protein-coupled receptors (GPCRs) (Fig. 2) . Importantly, and as predicted, compound 13 is highly CNS penetrant (BBR 5 7.5).
To verify that the predicted properties of selectivity, potency and CNS penetration resulted in D4 receptor activity in vivo, we evaluated the effects of compound 13 treatment on behaviour in wild-type and D4 receptor knockout (D4R-KO) mice ( Fig. 4c-f ), as well as in proprotein convertase 7 (PC7 encoded by Pcsk7) knockout mice (Supplementary Fig. 10a-d ) that display a similar D4R-KO phenotype. Although open field locomotor activity declined in vehicle-treated D4R wild-type (DR4-WT) animals ( Fig. 4c ), it remained high and showed little habituation in D4R-KO mice. Although the treatment with 0.7 mg kg 21 of compound 13 was without significant effect in either genotype, the 1 mg kg 21 dose reduced locomotion at 0-20 min 
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in D4R-WT animals. The same dose had no effect in D4R-KO mice. In the centre zone, vehicle-treated D4R-KO mice spent more time in this area at 21-60 min than D4R-WT controls (Fig. 4d ). Centre time in D4R-WT animals was enhanced at 0-20 min with both doses of compound 13; in D4R-KO mice it was attenuated at 41-60 min with the 1 mg kg 21 dose. In the hole-board test, head-poking was increased in vehicle-treated D4R-KO animals compared to D4R-WT controls (Fig. 4e ). In D4R-WT mice compound 13 augmented head-pokes in a dose-dependent fashion; only the 1 mg kg 21 dose attenuated headpoking in mutants. In the zero maze, open-area time was increased in vehicle-treated D4R-KO mice relative to D4R-WT controls (Fig. 4f ). Treatment of 1 mg kg 21 of compound 13 selectively increased D4R-WT open-area times to similar levels seen with the D4R-KO mice. With regards to PC7 mice, PC7-WT and D4R-WT responses were similar ( Supplementary Fig. 8a-d) . Although behaviours in PC7-KO vehicle controls essentially phenocopied those in vehicle-treated D4R-KO mice, compound 13 normalized PC7-KO responses to those of PC7-WT controls. By comparison, D4R-KO mice were largely unresponsive to compound 13-demonstrating high D4R selectivity. Nonetheless, compound 13 did not seem to be absolutely selective because in D4R-KO animals the 1 mg kg 21 dose attenuated head-poking in the hole-board test, implying some possible off-target actions at increased doses.
Automated invention
Using compound 13, we further expanded our objective to evolve ligands that were highly selective for D4 dopamine, CNS penetrant and a new chemotype. The evolution of compound 13 against these objectives resulted in the design of new morpholino compounds ( Fig. 4b and Supplementary Fig. 11 and Supplementary Tables 10  and 11 ). Compounds with the new isoindol-1-yl-ethyl-morpholino backbone were prominent in the prioritized final generation population of 10,000 structures (ranked fifth, sixth and ninth of the top 10 compounds in Supplementary Table 10 ), whereas most known D4 ligands are 1,4-disubstituted aromatic piperidines and piperazines (1, . However 1,4-DAPs are rather promiscuous substructures common in ligands for many biogenic amine GPCRs 43 . Therefore, the isoindol-1-yl-ethyl-morpholino analogues represent a new D4 chemotype. A library of 24 morpholino analogues (compounds 14-29) was then synthesized and profiled against our GPCR panel (Supplementary Table 11 and Supplementary Fig. 5 ). Individual R and S morpholino enantiomers were synthesized and assayed separately (chirality designated by prefix). To reduce complexity further, direct analogues with and without the carbonyl oxygen were synthesized (for example, compounds 20 and 21), as this atom was not predicted to be essential to the overall D4 selectivity profile (Fig. 2) .
The assays confirmed the predictions that the new morpholino compounds are generally highly selective for the D4 receptor compared with the other tested receptors (Fig. 2) . Seventeen of the compounds had affinities for the D4 dopamine receptor, ranging from Compounds containing the ethanone linker-group were generally less active than those with the ethyl linker. For compounds with the ethyl linker, the S enantiomer was more potent than the R enantiomer. Functional assays of an exemplar compound (R)-22 indicated inverse agonism at the D4 receptor ( Supplementary Fig. 3 ).
In agreement with the design objectives, the morpholinos displayed exquisite selectivity for the D4 dopamine receptor. Excluding the dopamine receptors, low positive Bayesian scores were observed for eight of the compounds against 5-HT 1A serotonin receptors, 16 of the compounds against the 5-HT 2A/B/C serotonin receptors, and almost all had very low scores for 5-HT 7 serotonin receptors. The off-target trends were confirmed when the compounds were profiled (Fig. 2) . The morpholino compounds, on average, bound to 3.4 targets (including D4 at K i , 10 mM) compared to 15.8 targets for the isoindole and benzolactam compounds. Seven of the active compounds had off-target activities for only 1 of the 20 receptors tested. Compound (S)-26 is the most selective compound with no measured affinity for any other screened receptor. Four compounds possessed both relatively high affinity (D4 K i ,1 mM) and two or fewer off-target activities out of the 20 GPCRs profiled ((S)-21, (S)-26, (S)-27 and (S)-28).
The morpholino series thus represents a new class of highly selective, brain-penetrant, D4 dopamine receptor ligands. Compounds (S)-27 (D4 K i 5 90 nM; D1 K i 5 5852 nM; BBR 5 2.0) and (S)-21 (D4 K i 5 182 nM, 5-HT 2A K i 5 3,545 nM) qualified as lead compounds that fulfilled all of our design objectives of novelty, high affinity for the D4 dopamine receptor, exquisite selectivity and CNS penetration. Clearly the automated design of a new class of ligands with a desired multitarget profile demonstrates that the method is able to generate novel, drug-like lead compounds directly by automated design.
Drug design from knowledge
We focused on the polypharmacology of bioaminergic GPCRs as a convenient test case, owing to the importance of multi-target profiles at these receptors for a variety of neuropsychiatric indications 4 a, Summary of the evolution of the prioritized benzolactam analogues (compounds 11a and 11b) from a parent isoindole analogue (compound 5). The full evolutionary pathway from compound 5 to 11b is shown in Supplementary Fig. 7 . b, Comparison of polypharmacology profiles for the Bayesian model score and experimental binding affinities (K i ) of compound 5 and benzolactam analogues (compounds 9a-11b) for the seven target objectives (a 1A , a 1B and a 1D compared to 5-HT 1A , D2, D3 and D4 receptors). On average, the selectivity ratios for the D2, D3, D4 and 5-HT 1A receptors for the synthesized benzolactams over the a 1 receptors are 2.8-, 59-, 58-and 312fold, respectively. In comparison, the average selectivity ratios for D2, D3, D4 and 5-HT 1A receptors for the isoindole analogues over the a 1 receptors are 0.27-, 2.1-, 1-and 14-fold, respectively. With respect to the algorithm prioritization for the benzolactam analogues ( Supplementary Table 8 ) against the multi-target objectives, the order of prioritization matches the experimentally determined order for the analogues (dichloro phenylpiperazine . 2-methoxy phenylpiperazine . 2-pyridine piperazine).
. In
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principle, the approach is applicable to all drug-target classes, limited only by the requirement for sufficient structure-activity data to create useful models [9] [10] [11] [12] . To extend polypharmacology profiling and hence de novo design it will be necessary to develop inference methods to build predictive bioactivity models that integrate all available structure-activity relationships, protein structure and protein sequence information together and combine data from diverse scoring functions into predictive frameworks 44, 45 .
De novo, automated compound design against multi-target profiles provides a powerful new approach for discovering new ligands and drug leads. The method is particularly useful as a new source of leads for polypharmacology profiles.
METHODS SUMMARY
Adaptive optimization. A library of historical chemical structure transformations was derived by mining the ChEMBL database 28 . Each transformation was systematically applied to every parent compound in each generation. Bayesian activity models 9, 46 were calculated for more than 784 proteins based on the ECFP6 fingerprint representation 46 of chemical structures of structure-activity data in ChEMBL. Each compound in every generation was scored against the panel of Bayesian models. ADME properties were calculated using StarDrop (Optibrium).
Synthetic accessibility was assessed using a previously published method 39 based on the statistical representation of fragments in ChEMBL and molecular complexity. The algorithm was programmed in Pipeline Pilot (version 7.5, Accelrys). Chemical synthesis. Details of the purchase, synthesis and purification of all compounds are provided in the Supplementary Information. Experimental testing. The predicted receptor profiles of all the compounds were assessed using standard radioligand binding and functional assay methods at the National Institute of Mental Health Psychoactive Drug Screening Program. The hERG assay was performed as previously described 47 . Metabolic stability was assessed as previously described 48 and brain penetration was assessed by determining the ratio of tested compound between brain and blood at a set time point following intraperitoneal or intravenous administration. For behavioural studies, compound 13 was dissolved in a 0.1% N,N-dimethylacetamide (DMA) with 15% 2-hydroxypropyl-b-cyclodextrin (Sigma-Aldrich) solution and injected intraperitoneally immediately before placement into the open field or 30 min before the zero-maze or hole-board tests as described 49, 50 using AccuScan (AccuScan Instruments), Noldus Observer XT 9.0 (Noldus Technologies), and Clever Sys TopScan software (Clever Sys), respectively. All behavioural data are presented as means 6 s.e.m and were analysed with SPSS 20 (IBM). Details of the in vivo experiments are described in the Supplementary Information. Supplementary Fig. 9 . b, Summary of the evolution of selective novel D4 dopamine ligands. Compound 13 is further evolved by selection for novelty and D4 selectivity into the morpholino analogues 18, 20 (R and S), 21 (R and S) and 27 (R and S). The full evolutionary pathway from compound 13 to 27 is shown in Supplementary Fig. 11 c- 
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Data sets. All machine learning and data mining of the medicinal chemistry structure-activity data were conducted on the ChEMBL database (release 1) and a pre-release (StARLite version 31) 28 . The ChEMBL database contains (release 1) more than 440,000 compounds abstracted in J. Med. Chem. and Bioorg. Med. Chem. Lett. from 1980 to May 2008. The ChEMBL database is available for download from the EBI. Chemical transformations. A database of chemical transformations was derived from systematically comparing sets of analogue compounds in ChEMBL 28 . Sets of analogues with defined structure-activity relationships were identified in ChEMBL 28 usually from individual journal articles. The transformations database was seeded with a set of common chemical transformations derived from medicinal chemistry knowledge. The transformations database was then expanded by systematically applying all existing transformations to each of the structures associated with each of the journal articles in ChEMBL. The resulting set of transformed compounds was compared to the published analogues. Analogues that were not present in the transformed set highlighted potential transformations that were missing from the transformation database, and were subsequently added to the database. This iterative mining method attempts to regenerate all the reported structures of every medicinal chemistry publication reported in ChEMBL. The chemical transformations were encoded in RXN format. The procedure was implemented in Pipeline Pilot. The current database contains more than 700 unique structural transformations. Bayesian models. Predictive polypharmacology profiling was undertaken using Bayesian activity models, based on our previously published approach 9 . The Bayesian method for polypharmacology profiling was chosen as it provided both good performance for noisy data sets and a high speed of calculation 51 . High confidence models were built using ChEMBL (release 1). Activity data were filtered to keep only activity end-point points that had half-maximum inhibitory concentration (IC 50 ), half-maximum effective concentration (EC 50 ) or K i values and where the ChEMBL confidence score was at least seven (protein assignment was direct or a homologue). A compound was considered active when the mean activity value was below 10 mM. All inactive compounds were assigned to the target 'none'. Following this procedure, 133,061 compounds remained with 215,967 activity end-points, which were used for model building. Multiple category Laplacian-modified naive Bayesian models were built with ECFP6 representations 52 for 784 targets. For each model the data were split in two for the validation step: compounds were clustered and assigned a cluster number. Clusters with an odd number were assigned to the test set, and the clusters with an even number were assigned to the training set. Models were built with the training set, and the test set was scored. The training set was scored using its own model as comparison. Finally, a model was built with all data and scored against itself-the training set and whole set should provide similar validation statistics. Statistics on the performance of the models are described in Supplementary Table  12 .
The results for the model containing all 785 targets were very similar to the models for the receptor subsets. Two analyses were used to assess the performance of the different models. The first analysis provides an overall score and does not need to specify a cut-off for distinguishing active from inactive compounds.
The area under the receiver operating characteristic (ROC) curve provides an indication of the ability of the model to prioritize active compounds over inactive compounds. The ROC curve is the plot of the true positive versus the false positive rate. However, it does not provide information on early enrichment, which was important in studies such as the present one in which only the top-ranking compounds were considered. Therefore the Boltzmann-enhanced discrimination of ROC (BEDROC) 53 was used, which solves the early enrichment issue by adding a weight to compounds recognized early. BEDROC was derived from the robust initial enhancement, and the sum of log of ranks test 54 , which provided a statistical test to assess which method performs better than random. The percentage of active compound retrieved in the top 5% is also calculated (recall 5 5%). The second analysis required a cut-off to make the distinction between active and inactive, as they varied with the rank of the compounds. For each model, the specificity (true negative rate), sensitivity (true positive rate), false positive rate, false negative rate, precision, F-measure and Matthews correlation coefficient (MCC) were calculated at different cut-off values. The cut-off providing the best MCC score was used, as it was shown to provide better performance 55 ( Supplementary Fig. 12 ). The quality of the models was assessed using an internal leave-one-out validation: one compound was part of the test set and was scored using the remaining data as the training set. Then the area under the ROC curve was calculated ( Supplementary Fig. 13) . A cut-off score was calculated to minimize the sum of the percentage misclassified for category members and for category non-members and used to classify compounds in the contingency table. An all data model for dopamine receptors only was built using data from a prerelease of ChEMBL (StARLite version 31), with similar numbers of compounds and end-points. The model was built without considering the confidence level of target assignment to gather as much data as possible. This model was used for initial calculation on the evolution of the isoindole series and the 2,3-dihydroindol-1-yl series. The quality of the models was assessed using the same procedures as described earlier. The results from the all data models and the high confidence models were very similar (for example, D2 models R 2 5 0.998, D4 models R 2 5 0.984). Profile prediction probabilities. The cut-off for a good prediction came from the validation steps for the model. From the test set, the cut-off value providing the best MCC value was used. For the 5-HT 1E receptor, a cut-off of zero was selected. For each ligand-target association, the probability of success was 0.5 (active or inactive where activity was defined as K i , 10 mM). To test whether the profile predictions were better than random, an exact binomial test was performed using R (version 2.8.1) (http://www.r-project.org), and the cumulative binomial probability was calculated. Adaptive optimization. The adaptive optimization procedure involves defining a parent population of compounds (P P ), of at least one molecule, and a set of n ideal achievement objectives {x O 1 , … , x O n }, where n is at least 1. The parent population of compounds for each generation (G) is defined as P P(G 5 n) , in which n 5 0 for the initial population. All of the members of the parent population (P P ) are subjected to all possible transformations, to maximize the pool of molecules in the transformed population (P T ). Each member of the transformed population is scored using the calculated predictions and molecular properties and ranked relative to the achievement objectives {x O 1 , … , x O n }. Pareto ranking is a common method for prioritizing multiple criteria 17 . The Pareto frontier maps a surface in which all solutions are considered equivalent (non-dominant)-where an increase in one objective leads to a decrease in at least one or more other objectives. However, finding a Pareto optimal solution becomes difficult when many objectives are considered 56 , hence a vector scalarization procedure is used 37 . Multi-objective prioritization is performed using vector scalarization, by describing the calculated parameters for a compound (A) as a multi-dimensional coordinate. The results are ranked by the magnitude of the vector jjajj between the multi-dimensional coordinates of predicted values of the chemical structure of a compound (A) and the defined ideal achievement objective point, (O), with the shortest vector length closest to the ideal in multi-dimensional space, being ranked the highest:
in which the ideal achievement objective point has the coordinates (x O 1 , … , x O n ), and calculated values of the compound A form the coordinates (x A 1 , … , x A n ). For subsequent generations, prioritized individuals with calculated properties and parameters that satisfy defined thresholds are assigned to an elite population (P E ), and those that fail are assigned to a non-elite population (P N ), of which n random members form a random population (P R ). For all the calculations performed, P E has a maximum size of 10,000 and P R a maximum size of 500. The new parent population (P P(G 5 n 1 1) ) is created by merging P E and P R (that is, P P(G 5 n 1 1) 5 P E(G 5 n) 1 P R(G 5 n) ). This new population is subjected to another transformation process. The new parent population P P from each generation is also added to a combined pool of all observed parents (P Pall ).
The population of transformed compounds from the last iteration and the pooled parent population are combined and all duplicates and compounds failing structure valency rules are removed to produce a merged population (P M ) of unique members (P M 5 P Pall 1 P T ). Properties and parameters (for example, Bayesian activity models values, physicochemical properties and predicted ADME properties) are calculated for each individual in P M . Each member population P M is evaluated against the achievement objectives {x O 1 , … , x O n }, as described above. The entire process is repeated until a stop condition is satisfied.
Novelty is assessed by comparing the generated compound with compounds in ChEMBL, either as an exact match or by comparison of the Murcko framework 41 , depending on whether the objectives are defined in terms of new compounds or new chemotypes. Novelty is filtered depending on the goals. ADME properties and CNS penetration are calculated using previously publishing Gaussian process models 57, 58 as implemented in StarDrop (Optibrium). A synthetic accessibility score, representing historical synthetic knowledge, is calculated using a previously published algorithm 39 . The synthetic accessibility score combines the observation of fragments in ChEMBL and a complexity penalty. A limitation of the ECFP6-Bayesian prediction method is that fingerprints cannot distinguish stereochemistry if the stereochemistry is not encoded in the training data. In the ChEMBL database only 43% of the chiral compounds with chiral centres have their stereochemistry fully defined, thus it is not possible to distinguish between R ARTICLE RESEARCH
